Crossmark

Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study

Crossref DOI link: https://doi.org/10.1038/s41397-024-00330-5

Published Online: 2024-03-18

Published Print: 2024-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fragoulakis, Vasileios

Koufaki, Margarita-Ioanna

Joefield-Roka, Candace

Sunder-Plassmann, Gere http://orcid.org/0000-0002-9253-9921
Mitropoulou, Christina http://orcid.org/0000-0002-9184-4668
Funding

Funding for this research was provided by:

European Commission (668353)
License Information

Text and Data Mining valid from 2024-03-18

Version of Record valid from 2024-03-18
More Information

Article History

Received: 5 February 2024

Revised: 17 February 2024

Accepted: 5 March 2024

First Online: 18 March 2024

Competing interests

: The authors declare no competing interests.

: The study was approved by ethics committee of the Medical University of Vienna, Vienna, Austria.

Document is current

Any future updates will be listed below